Arachidonic acid-induced Ca2+ release from isolated sarcoplasmic reticulum.
Arachidonic acid has been shown to release Ca2+ from isolated skeletal and cardiac sarcoplasmic reticulum (SR) vesicles. The release took place nearly equally well from all fractions of the SR and was only partially inhibited by ruthenium red, suggesting that some other pathway is involved in addition to the SR Ca2+ release channel. Arachidonic acid increased SR Ca2+ efflux even in the presence of several different SR Ca2+ pump inhibitors. It also had considerably less effect on uptake measured in the presence of oxalate and did not appear to inhibit Ca(2+)-dependent ATPase activity. Thus, the SR Ca2+ pump also appears to be minimally perturbed by arachidonic acid. Arachidonyl CoA was more effective at releasing Ca2+ than the parent compound. Arachidonic acid effects were not inhibited by lipoxygenase or cyclooxygenase inhibitors, suggesting that no eicosanoids are involved in the effects under study here. Flunarizine, cinnarizine and propyl-methylenedioxyindene inhibited the Ca2+ release induced by arachidonic acid. The effects of arachidonic acid appear to depend on the ratio of arachidonic acid to membrane vesicles.
Dettbarn
C
C
Department of Physiology and Biophysics, University of Texas Medical Branch, Galveston 77555-0641.
Palade
P
P
D000818:Animals; D016718:Arachidonic Acid / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D001842:Bone and Bones; D002118:Calcium / Q000378:metabolism*; D000252:Calcium-Transporting ATPases / Q000187:drug effects*; D004285:Dogs; D005444:Flunarizine / Q000494:pharmacology; D006321:Heart; D010070:Oxalates / Q000494:pharmacology; D011817:Rabbits; D012430:Ruthenium Red; D012519:Sarcoplasmic Reticulum / Q000187:drug effects* / Q000378:metabolism
D010070:Oxalates; D012430:Ruthenium Red; D016718:Arachidonic Acid; D000252:Calcium-Transporting ATPases; D005444:Flunarizine; D002118:Calcium